Cargando…

Epigenetic modulation with oral histone deacetylase (HDAC) inhibitor as a new treatment option in JIA

Detalles Bibliográficos
Autores principales:	Vojinovic, J, Furlan, A, Damjanov, N, D’Urzo, C, Dinarello, CA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194520/ http://dx.doi.org/10.1186/1546-0096-9-S1-P166

Ejemplares similares

DNase I levels and disease outcome in JIA patients treated with etanercept
por: Lazarević, D, et al.
Publicado: (2011)

DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
por: Vojinovic, J, et al.
Publicado: (2008)

Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2021)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Epigenetic control of signaling networks involved in interleukin-18-induced cardiac hypertrophy and its attenuation by pan-histone deacetylase inhibitors
por: Majumdar, Gipsy, et al.
Publicado: (2010)

Inflence of clinical and genetic characteristics on ability to achive and maintain remission in JIA patients on etanercept treatment
por: Lazarevic, Dragana S, et al.
Publicado: (2014)

The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
por: Vaca, Hugo Rolando, et al.
Publicado: (2021)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
por: Bassett, Shalome A., et al.
Publicado: (2014)

Does standard phisiotherapy influence the health-related quality of life of JIA patients?
por: Mendonça, TMS, et al.
Publicado: (2011)

Histone antibodies as a biomarker of uveitis in JIA
por: Nordal, Ellen B, et al.
Publicado: (2014)

MEFV mutations in systemic JIA
por: Aktay Ayaz, N, et al.
Publicado: (2008)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

The swedish paediatric JIA-registry
por: Magnusson, Bo
Publicado: (2014)

Puberty and disease activity in JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

Clinical classification of JIA in Albania
por: Vula, Aurel, et al.
Publicado: (2014)

Embryogenic potential and expression of embryogenesis-related genes in conifers are affected by treatment with a histone deacetylase inhibitor
por: Uddenberg, Daniel, et al.
Publicado: (2011)

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors
por: Galán, María, et al.
Publicado: (2016)

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
por: Wagner, Julia M., et al.
Publicado: (2010)

Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs
por: Wang, Yuren, et al.
Publicado: (2017)

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
por: Luo, Yuxiang, et al.
Publicado: (2020)

HTLV-1 inhibits stress granules formation by interacting with the histone deacetylase 6 (HDAC6)
por: Legros, Sébastien, et al.
Publicado: (2009)

Determing an “autoimmune” phenotype in systemic JIA
por: Fischer, N, et al.
Publicado: (2011)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

Evaluation of the JIA treatment with adalimumab in ukraine
por: Ponochevna, Elena, et al.
Publicado: (2014)

Effect of ANA positivity on clinical picture of the JIA: should ANA positive JIA be classified as a different group?
por: Polat, Adem, et al.
Publicado: (2011)

Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors
por: Urias, Beatriz Silva, et al.
Publicado: (2022)

Sox9 represses gene expression via histone deacetylase activity
por: Tsuda, M, et al.
Publicado: (2003)

Histone deacetylase inhibition leads to neuroprotection through regulation on glial function
por: Wu, Xuefei, et al.
Publicado: (2013)

Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
por: Susic, G, et al.
Publicado: (2008)

Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers
por: Wagner, F. F., et al.
Publicado: (2015)

Ocular threat in juvenile idiopathic arthritis (JIA)
por: Marvillet, I, et al.
Publicado: (2008)

Use of internet in adolescents and young adults with JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

JIA-like in a boy with Ataxia-telangiectasia
por: Furtado, Filipa, et al.
Publicado: (2014)

Chromatin remodeling induced by histone deacetylase inhibitors (HDACis) in HeLa, NIH 3T3 and HepG2 cells
por: Felisbino, Marina B, et al.
Publicado: (2013)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

In-Silico Analysis of Chromatin Modifiers and Profiling of Histone Deacetylases (HDAC's) in Human Oral Cancer
por: Sajnani, Anand K., et al.
Publicado: (2021)

Influence of TNFα–308 and T676G TNF-RII polymorphism on response to etanercept and posibility to discontinue tretment
por: Vojinovic, J, et al.
Publicado: (2011)

Influence of psychostimulants and opioids on epigenetic modification of class III histone deacetylase (HDAC)-sirtuins in glial cells
por: Sivalingam, Kalaiselvi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hhf9ojsl84kvt86gn9quuf8shj